1. CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- Author
-
Daniela Ferrara, Ricardo N Louzada, Nadia K. Waheed, Emily Cole, and Eduardo A. Novais
- Subjects
Vascular Endothelial Growth Factor A ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,genetic structures ,Angiogenesis Inhibitors ,Macular Degeneration ,03 medical and health sciences ,0302 clinical medicine ,Optical coherence tomography ,Ophthalmology ,Age related ,Humans ,Medicine ,Clinical Trials as Topic ,medicine.diagnostic_test ,business.industry ,General Medicine ,Optical coherence tomography angiography ,Macular degeneration ,medicine.disease ,Choroidal Neovascularization ,eye diseases ,Clinical trial ,030104 developmental biology ,Choroidal neovascularization ,Angiography ,030221 ophthalmology & optometry ,sense organs ,Tomography ,medicine.symptom ,business ,Tomography, Optical Coherence - Abstract
To describe qualitative and quantitative optical coherence tomography (OCT) angiography (OCTA) parameters for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and their applicability as potential clinical trial endpoints.A review of current literature related to the topic of OCTA and AMD.There are a number of promising OCTA parameters that can be used to diagnose the presence of CNV and to monitor the activity and progression of the lesion, pre- and post-treatment morphological characteristics, CNV dimensions, and automated quantitative parameters such as vessel density.The OCTA parameters described in this review have promise for the future development of clinical trial endpoints, but require further validation before they can be widely used.
- Published
- 2016
- Full Text
- View/download PDF